Analysis reveals S100A8/A9 drives T cell exhaustion, compromising therapeutic efficacy in multiple myeloma, implying a need for targeted interventions.
Key Points
Patients with high S100A8/A9 had shorter progression-free survival, indicating a link to T cell exhaustion.
Higher S100A8/A9 levels corresponded with reduced cytokine production and cytotoxicity in T cells.
Blocking S100A8/A9 with monoclonal antibodies restored functionality and T cell responses against tumor cells.
These findings necessitate further exploration of S100A8/A9 as a therapeutic target in multiple myeloma.